Ambros Therapeutics, a clinical-stage biotechnology company headquartered in Irvine, California, announced today it has successfully raised $125,000,000 from investors. This significant capital infusion will support the company's mission to develop innovative and transformative medicines for diseases with a high unmet medical need.
The company's lead investigational program targets complex regional pain syndrome type 1 (CRPS-I), a devastating rare metabolic bone disease. CRPS-I causes severe, unrelenting, and frequently lasting pain following trauma or injury, leading to significant functional loss, sleep disturbance, and a diminished quality of life for patients. Ambros Therapeutics is currently advancing its Phase 3 pivotal trial, CRPS-RISE, which represents a first-in-class approach to addressing this condition that currently has no FDA-approved therapies.
The successful securing of $125,000,000 underscores investor confidence in Ambros Therapeutics' clinical pipeline and its potential to deliver novel treatments for debilitating diseases. This funding is particularly significant given the advanced stage of its CRPS-RISE trial and the urgent need for therapies in this area. The newly secured capital is primarily intended to accelerate the ongoing clinical development of CRPS-RISE, supporting the extensive resources required for a Phase 3 pivotal trial. Furthermore, the funds will support the expansion of the company's research and development capabilities, enabling further exploration of new therapeutic candidates and strengthening its scientific foundation.
This investment is critical for Ambros Therapeutics as it moves closer to potentially providing relief for patients with CRPS-I and other conditions lacking effective treatments. The company remains focused on advancing its programs through clinical trials, with an outlook toward expanding its impact within the biotechnology landscape and addressing critical patient needs.
.png&w=3840&q=75)
